BioCentury | Dec 5, 2011
Strategy

Lundbeck psyched up

...and Japan, but Lundbeck has co-promotion rights in both territories. The Takeda deal also includes Lu AA24530...
BioCentury | Jul 6, 2009
Clinical News

Lu AA24530: Phase II data

...from a double-blind Phase II trial in 652 patients showed 5, 10 and 20 mg Lu AA24530...
...were low and similar to duloxetine. The company granted Takeda rights to co-develop and co-commercialize Lu AA24530...
...2007). H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA24530...
BioCentury | Jul 3, 2009
Clinical News

Lundbeck meets Phase II depression endpoint

...a Phase II trial to treat major depressive disorder showed 5, 10 and 20 mg Lu AA24530...
BioCentury | Feb 16, 2009
Strategy

Lundbeck-Ovation pipeline

...GAD) Ph III Nalmefene [BioTie (HSE:BTH1V)/ Somaxon (NASDAQ:SOMX)] Opioid receptor antagonist Alcohol dependence Ph III Lu AA24530...
BioCentury | Nov 19, 2007
Strategy

Lundbeck's products

...atypical antipsychotic Psychosis Ph II Lu AA21004 Serotonin modulator and stimulator Depression Ph II Takeda Lu AA24530...
BioCentury | Nov 19, 2007
Strategy

Reloading in a hurry

...family are Lu AA21004 , which is to enter Phase III testing this quarter, and Lu AA24530...
...agreement with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan). The deal covers Lu AA21004 and Lu AA24530...
...trial this quarter. Also, in October, the partners started a 600-patient Phase II trial of Lu AA24530...
BioCentury | Oct 29, 2007
Clinical News

Lu AA24530: Phase II started

...10). H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Lu AA24530...
BioCentury | Sep 10, 2007
Company News

Lundbeck, Takeda deal

...serotonin modulator and stimulator, is in Phase II testing to treat major depressive disorder (MDD). Lu AA24530...
BioCentury | Sep 6, 2007
Company News

H. Lundbeck, Takeda in neurology deal

...modulator and stimulator, is in Phase II testing to treat major depressive disorder (MDD), and Lu AA24530...
BioCentury | Dec 19, 2005
Clinical News

Lu AA24530: Phase I started

...a Phase I trial for Lu AA 24530. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Product: Lu AA24530...
Items per page:
1 - 10 of 10